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Copper‑64 (T1/2 = 12.7 h; b+: 17.8%, b‑: 41%) has applica‑
tions in both positron emission tomography (PET) imaging and 
targeted radiotherapy of cancer. Copper‑64 radiopharmaceuticals 
have shown tumor growth inhibition with a relatively low radiation 
dose in animal models; however, the mechanism of cytotoxicity has 
not been fully elucidated. Here, we report an investigation on the 
potential role of the tumor suppressor protein p53 in trafficking 
64Cu to tumor cell nuclei. Two EGFR expressing human colorectal 
cell lines (HCT 116 +/+ and HCT 116 ‑/‑) that are positive or 
negative for p53 expression respectively, were used to compare 
internalization and nuclear localization of [64Cu]copper acetate 
and of 64Cu‑DOTA‑cetuximab, a monoclonal anti‑EGFR antibody. 
[64Cu]copper acetate uptake into cells was similar between the 
two cell lines during a 24 h time course. In contrast, the uptake 
of [64Cu]copper acetate in the nuclei of HCT 116 +/+ cells was 
significantly higher than in HCT 116 ‑/‑ cells (p < 0.0001) at 24 
h. There was no difference in receptor binding, receptor‑mediated 
internalization, and efflux of 64Cu‑DOTA‑cetuximab between 
the two HCT 116 cells lines. However, nuclear localization of 
64Cu‑DOTA‑cetuximab showed increased uptake in the nuclei of 
HCT 116 +/+ cells as early as 4 h. These data demonstrate that 
64Cu is delivered to tumor cell nuclei in a p53 positive cell line in 
significantly greater amounts than in p53 negative cells by both 
non‑specific and receptor‑mediated uptake mechanisms.
Introduction
There has been increasing interest in the use of copper radio‑
pharmaceuticals for PET imaging and/or targeted radiotherapy of 
cancer. Copper‑64 (T1/2 = 12.7 h; b+: 0.655 MeV; 17.8%; b‑: 0.573 
MeV; 41%) emits both b+ and b‑ radiation for PET and therapy 
applications, while 67Cu (T1/2 = 62 h; 100% b‑: 0.576 MeV max) is 
a b‑ emitter that has shown success in radioimmunotherapy of non‑
Hodgkin’s lymphoma in tumor‑bearing mice1‑3 and in humans.4,5 
We previously observed that 64Cu‑labeled tumor‑targeting agents 
showed enhanced therapeutic efficacy of an internalizing 64Cu‑labeled 
anti‑colorectal carcinoma mAb, 64Cu‑labeled 1A3, in a tumor‑bearing 
hamster model compared to 90Y‑ or 131I‑labeled mAbs in the same 
animal model.6,7 We also evaluated the 64Cu‑labeled somatostatin 
analogs octreotide and Y3‑TATE as therapeutic agents, and although 
we did not observe complete tumor remissions, we did see tumor 
growth inhibition at relatively low radiation doses to the tumors 
(465‑600 cGy).8,9
Particularly in the area of receptor‑targeted therapy agents,10,11 
the intracellular fate of the radiopharmaceuticals following binding 
to cell surface receptors has been a topic of interest.12,13 It was 
previously demonstrated that 111In from 111In‑DTPA‑octreotide 
(Octreoscan®), an imaging agent clinically approved for somatostatin‑ 
receptor positive tumors in the United States and Europe, showed 
uptake in tumor cell nuclei.12 This suggests a possible mechanism for 
the therapeutic efficacy of this Auger electron‑emitting radiopharma‑
ceutical. We demonstrated that 64Cu from 64Cu‑TETA‑octreotide 
was significantly localized in the nuclei of AR42J rat pancreatic tumor 
cells in cell culture, whereas 111In from 111In‑DTPA‑octreotide was 
localized to tumor cell nuclei in much smaller amounts.14 Although 
64Cu only emits 2 Auger electrons per decay, it has been reported 
that the recoil energy from the transmutation of this radionuclide 
in the vicinity of DNA can cause lethal damage to the cell.15 These 
data suggested that delivery of 64Cu to the cell nuclei may enhance 
the therapeutic effect of beta‑emitting, tumor targeting copper radio‑
pharmaceuticals.
Because copper can readily form oxygen radicals, free copper 
essentially does not exist in vivo.16 Several chaperones have been 
identified that transport copper to various organelles in mammalian 
cells (for a review on this subject, see ref. 17). Copper is trans‑
ported into the cell via hCtr1 (human copper transporter). Several 
chaperones serve to traffic copper between cellular compartments. 
Cox17 carries copper to the mitochondria for incorporation into 
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p53 and 64Cu transport to tumor cell nuclei
 cytochrome c. Copper can also be incorporated into nascent Cu/Zn 
SOD via the copper chaperone CCS. The Wilson disease P‑type 
ATPase receives copper from HAH1 in the trans‑golgi‑network, where 
copper binds to ceruloplasmin during synthesis. Metallothionein is 
thought to play a role as a copper storage pool within the cell.18 To 
date, no chaperones have been identified that traffic copper to the 
cell nucleus. There are proteins common in tumors and other tissues 
that may play a role in the transport of copper to the nucleus. The 
tumor suppressor protein p53 is a critical cellular mediator of the 
response to oxidative stress and genotoxic damage. Upon activation, 
p53 accumulates in the nucleus where it transcriptionally activates 
the expression of a number of proteins. There is in vitro evidence that 
copper may displace zinc in the p53 structure.19
In addition to the possibility that 64Cu might bind to p53 itself, 
there is also evidence that p53 facilitates the transport of other 
copper‑based proteins to the nuclei of tumor cells. Azurin is a cupre‑
doxin protein secreted by Pseudomonas aeruginosa. It has been shown 
to have cytotoxic effects on J774 macrophages and human breast 
cancer cells.20,21 The induction of apoptosis by azurin is independent 
of its redox activity and involves complex formation with p53 and 
translocation to the nucleus.22‑24
Here we report on the transport of 64Cu to the nuclei of 
HCT116 cells lines that are either p53 WT or p53 negative (herein 
referred to as HCT 116 +/+ and HCT 116 ‑/‑). We evaluated 
[64Cu]copper acetate, which will bind to proteins in serum and be 
taken up by cells via the hCtr1 transporter, as well as the EGFR 
antibody 64Cu‑DOTA‑cetuximab, which will be delivered to the 
EGFR‑positive HCT 116 cell lines by a receptor‑mediated pathway. 
Cetuximab was the first monoclonal antibody targeted against the 
ligand‑binding site of EGFR to be approved by the FDA for the 
treatment of patients with EGFR‑expressing, metastatic colorectal 
carcinoma.25‑27 We demonstrate a potential pathway for the traf‑
ficking of copper (in the form of 64Cu) to the nuclei of tumor cells 
via the tumor suppressor protein, p53.
Results
Internalization and nuclear uptake of [64Cu]copper acetate. 
HCT 116+/+ and HCT 116‑/‑ cells were incubated with [64Cu]copper 
acetate over a 24 h time course to measure internalization. 64Cu 
accumulated in both lines over time and reached approximately 
20% ID/mg at 24 h. Minimal difference was observed between the 
two cell lines (Fig. 1A). p53 status thus had no apparent influence 
on transport of 64Cu via the hCtr1 transporter. The difference in 
nuclear uptake of 64Cu, however, was quite significant (Fig. 1B). 
At the end of the 24 h time course, 64Cu accumulation in the 
nuclei was two‑fold higher in HCT 116 +/+ cells compared HCT 
116 ‑/‑ cells (8.26 ± 0.13 vs. 4.05 ± 0.07% ID/mg cellular protein, n = 3, 
p < 0.0001). Even though uptake of 64Cu from [64Cu]copper acetate 
was not influenced by p53 status, transport of this radiometal to the 
nucleus was significantly higher in the p53 expressing cell line.
To test for the integrity of the HCT 116 cell lines utilized 
in this study, which have been passaged for several decades, and 
to ensure the absence of clonal artifacts, HCT 116+/+ cells were 
treated with p53 siRNA (short interfering RNA, silencing RNA) 
to downregulate p53 mRNA and p53 protein. After three days, 
these cells were exposed to 25 mCi of [64Cu]copper acetate, and 
cell nuclei were isolated and measured for 64Cu activity. Nuclear 
uptake was significantly lower in HCT 116+/+ cells treated with 
p53 siRNA (0.126 ± 0.008% ID/mg, n = 3) compared to untreated 
HCT 116 +/+ cells (0.252 ± 0.003% ID/mg, n = 2, p < 0.01). There 
was no statistical significance between down‑regulated HCT 116+/+ 
cells and HCT 116‑/‑ cells (0.165 ± 0.033% ID/mg, n = 2, p = 0.23). 
Thus, downregulation of p53 mRNA and protein in HCT 116+/+ 
cells led to nuclear localization of 64Cu more similar in quantity to 
HCT 116‑/‑ cells than to HCT 116+/+ cells. This control experiment 
reduces the probability that clonal artifacts were responsible for the 
64Cu nuclear uptake patterns observed in the two HCT 116 clones.
Synthesis and receptor binding of 64Cu‑DOTA‑cetuximab. 
Next, experiments were performed to determine whether this 
difference would be observed when 64Cu enters the cells via a recep‑
tor‑mediated pathway. HCT 116 cells express EGFR, and we chose 
64Cu‑DOTA‑cetuximab as a vector for bringing 64Cu into HCT 
116 cells. Cetuximab is a humanized anti‑EGFR monoclonal antibody 
and has been approved by the FDA for treatment of EGFR‑positive 
metastatic colorectal cancer and advanced head‑and‑neck cancer. 
DOTA is a well‑characterized chelator for copper, and it is 
known that 64Cu can dissociate from the 64Cu‑DOTA complex 
in vivo.32 64Cu‑DOTA‑cetuximab was produced with a specific 
activity of 10 –15 mCi/mg [0.37–0.56 MBq/mg; 1.5–2.3 nCi/fmol 
(560–860 Bq/fmol)]. Initial radiochemical purity ranged from 
75–100%. For yields < 95%, 64Cu‑DOTA‑cetuximab was chal‑
lenged with 5 ml of 10 mM EDTA to complex free 64Cu. 
64Cu‑DOTA‑cetuximab was then isolated with a miniature size 
exclusion column, resulting in final radiochemical purities ranging 
from 98 ‑ 100%. Saturation receptor binding experiments with 
64Cu‑DOTA‑cetuximab and isolated HCT 116 +/+ and HCT 116 
‑/‑ cell membranes showed that there was no significant difference 
in the binding characteristics between the two cell lines (Fig. 2). 
The dissociation constant (Kd) was 0.95 ± 0.26 nM for HCT 116
+/+ 
cells and 1.13 ± 0.22 nM for HCT 116‑/‑ cells. These values are 
comparable to dissociation constants reported for unmodified cetux‑
imab, which range from 0.15–1.2 nM.33,34 Maximum EGF receptor 
densities (Bmax) were very similar as well: 1,950 ± 180 fmol/mg for 
HCT 116+/+ cells, and 2,180 ± 150 fmol/mg for HCT 116‑/‑ cells. 
It was important to demonstrate that EGF receptor numbers were 
comparable for both cell lines and were not dependent on their p53 
status in order to exclude the possibility that a difference in receptor 
numbers would confound the results of internalization, nuclear 
uptake, and efflux studies with 64Cu‑DOTA‑cetuximab.
Internalization and nuclear uptake of 64Cu‑DOTA‑cetuximab. 
These experiments were performed in the same manner as 
described for [64Cu]copper acetate. Figure 3A shows the uptake 
of 64Cu‑DOTA‑cetuximab into both HCT 116 cell lines. As was 
the case with [64Cu]copper acetate, internalization was similar in 
both lines. However, uptake did not increase between the 4 h and 
24 h time point. It is possible that the receptor‑mediated uptake of 
64Cu‑DOTA‑cetuximab was saturated at 4 h, whereas non‑specific 
uptake of [64Cu]copper acetate increased over the 24 h time course. 
At 24 h the total amount of internalized 64Cu‑DOTA‑cetuximab was 
43.7 ± 1.3% ID for HCT 116+/+ cells vs. 42.2 ± 3.3% ID for HCT 
116‑/‑ cells (P = 0.68, N = 6, data not shown). As expected from similar 
Kd and Bmax values for the interaction of 
64Cu‑DOTA‑cetuximab 
and the EGF receptor on the two HCT 116 cell lines, a difference 
in receptor‑mediated endocytosis of 64Cu‑DOTA‑cetuximab could 
not be observed.
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When isolated nuclei were measured for 64Cu activity after incu‑
bation with 64Cu‑DOTA‑cetuximab (Fig. 3B), numbers were higher 
in HCT 116+/+ cells compared to HCT 116‑/‑ cells (0.56 ± 0.05% 
vs. 0.36 ± 0.03% of internalized activity/mg cellular protein at 
24 h, P < 0.001, N = 6). Those values correspond to 10.3 ± 1.0% 
and 7.0 ± 0.5% of internalized 64Cu‑DOTA‑cetuximab (P = 0.01, N 
= 6, data not shown). In contrast to the analogous experiment with 
[64Cu]copper acetate, when a significant difference had not been 
seen at early time points, more 64Cu from 64Cu‑DOTA‑cetuximab 
appeared in the nuclei of HCT 116+/+ cells as early as 1 h, with the 
difference being statistically significant at 4 h (0.75 ± 0.09% vs. 
0.47 ± 0.05% of internalized activity/mg, p = 0.02, n = 6).
Efflux of 64Cu‑DOTA‑cetuximab. We hypothesize that 64Cu 
dissociates from 64Cu‑DOTA‑cetuximab and is complexed by a 
different protein before entering the cell nucleus. It is possible that 
this new complex also translocates to other cell compartments or 
leaves the tumor cell. To rule out that the observed difference in 
nuclear uptake between the two HCT 116 cell lines resulted from 
a variation in release of 64Cu into the medium, 64Cu efflux was 
monitored for 20 h after an uptake period of 4 h. Figure 4 shows 
the efflux profiles of both cell lines. Both cell lines retained compa‑
rable amounts of 64Cu from internalized 64Cu‑DOTA‑cetuximab 
throughout the time course, with the exception of increased efflux 
of 64Cu from HCT 116‑/‑ cells at 4 h. This time point may be an 
outlier, and the overall profiles suggest that the difference in 64Cu 
efflux between HCT 116 cell lines is minimal.
Discussion
Copper is one of the most important trace metals in humans, 
being surpassed in abundance only by iron and zinc.35 Therefore, 
mechanisms for copper uptake, transport and excretion exist within 
all living cells. Molecular imaging and targeted radiotherapy can 
take advantage of these mechanisms, e.g., by developing strategies 
to deliver radioactive isotopes like 64Cu or 67Cu to target cells. Due 
to its cytotoxicity, however, copper exists in biological systems only 
in a chelated species, bound by small molecules or proteins. Many 
of these copper binding proteins have been identified, such as the 
ubiquitous copper transporter hCtr1, or the metallochaperone CCS, 
which delivers the metal to the copper redox enzyme superoxide 
dismutase.36 Copper also exists in the cell nucleus and 
can interact with DNA; however, it is not known how 
copper enters the nucleus or which proteins may assist 
in its transport.
In the case of 64Cu, nuclear localization may have 
an additional effect on targeted radiotherapy of cancer. 
If transported to the nucleus, 64Cu from radiophar‑
maceuticals may have improved tumor cell killing 
properties in tumors, in part due to the delivery of 
a higher radiation dose to nuclear DNA. This extra 
dose comes from two Auger electrons with energies 
of 6.5 keV (22.5%) and 840 eV (57.7%), which are 
emitted by 64Cu. According to the MIRD database,37 
the range for the 6.5 keV electron is less than 1.5 mm 
in soft tissues, while the range for the 840 eV electron 
is only 0.05 mm. The diameter of HCT 116 tumor 
cell nuclei was determined to be 12–13 mm, therefore, 
nuclear localization is clearly necessary to bring tumor 
cell DNA in range of these Auger electrons. Another potential mode 
of cell killing is caused by the recoil energy associated with the trans‑
mutation of 64Cu nuclei to stable 64Ni (b+ decay) or 64Zn (b‑ decay). 
Apelgot and colleagues proposed that this mode of cell killing may 
be important if the decays occur within the DNA molecule itself, as 
DNA is highly sensitive to changes in its structure.15
We previously demonstrated that 64Cu localized to the nuclei 
from 64Cu‑TETA‑octreotide in AR42J rat pancreatic tumor cells,38 
and from 64Cu‑TETA‑Y3‑TATE in A427‑7 human non‑small cell 
lung carcinoma cells.39 64Cu‑CB‑TE2A‑Y3‑TATE is a very stable 
copper complex, and no nuclear accumulation has been observed 
with this somatostatin analogue over 24 h.39 This finding supports 
the hypothesis that 64Cu must dissociate from its chelator before 
entering the nucleus. Given the lack of free copper ions in living 
systems, a yet unidentified binding partner involved in copper traf‑
ficking to the nucleus almost certainly exists.
We present research indicating that the tumor suppressor protein 
p53 is directly or indirectly involved in the process of copper 
transport to tumor cell nuclei. 64Cu administered as [64Cu]copper 
acetate and 64Cu‑DOTA‑cetuximab entered the nuclei of HCT 
116+/+ cells, which express p53, in significantly greater amounts 
than was the case with HCT 116‑/‑ cells (Figs. 1B and 3B), which 
lack both p53 alleles. In the case of [64Cu]copper acetate, the 
metal is transported into the tumor cells via the hCtr1 transporter. 
64Cu‑DOTA‑cetuximab, a monoclonal chimeric antibody against 
the EGF receptor, enters the cell by receptor‑mediated endocytosis. 
Different uptake mechanisms may account for the observation that 
the uptake of 64Cu‑DOTA‑cetuximab into HCT 116+/+ nuclei was 
significantly increased after 4 h of exposure to the radiopharma‑
ceutical (Fig. 3B), whereas a significant increase of [64Cu]copper 
acetate uptake occurred only at 24 h (Fig. 1B). Control experi‑
ments showed that uptake of [64Cu]copper acetate (Fig. 1A) and 
64Cu‑DOTA‑cetuximab (Fig. 3A), as well as receptor binding 
(Fig. 2) and efflux of 64Cu‑DOTA‑cetuximab (Fig. 4) are not 
significantly different between p53 positive and negative cell lines. 
Thus, increased trafficking of 64Cu into HCT 116+/+ cell lines is not 
confounded by increased uptake or reduced efflux.
p53 protein is maintained at very low levels in the absence of 
cellular stress.40 It can be activated by many conditions such as 
Figure 1. Internalization (A) and nuclear localization (B) of [64Cu]copper acetate in HCT 
116 cell lines positive (£) and negative (p) for p53 (N = 3) in %ID/mg.
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DNA damage, hypoxia, chromosomal aberrations, telomere short‑
ening and others, whereupon it accumulates in the nucleus,41 acting 
as a sequence‑specific transcriptional regulator. Copper toxicity is 
correlated with apoptotic cell death, and translocation of p53 from 
the cytosol into the nucleus has been shown to occur in cells treated 
with 200 mM copper supplied as cupric sulfate.42 Our study shows 
that presence of p53 in turn increases the amount of 64Cu that is 
transported to the nucleus of HCT 116 cells. Copper is capable of 
displacing zinc from metal‑binding sites in proteins and has been 
shown to bind to p53 in vitro.19 Thus one possibility is that p53 
itself is responsible for the increased transport of 64Cu into the nuclei 
of HCT 116+/+ cells. We are currently examining another option, 
namely that one of the many binding partners of p53 complexes 
64Cu and is transported to the nucleus together with p53. One 
promising candidate is metallothionein, which is involved in the 
intracellular storage of metal ions like zinc and copper, and which 
has been shown to physically interact with p53 by co‑immunopre‑
cipitation with both anti‑p53 and anti‑metallothionein antibodies.43 
A third potential mechanism involves proteins from genes whose 
expression is upregulated by p53 after exposure to the radiocopper. 
Oligonucleotide array studies in neurons identified several p53 target 
genes which are differentially regulated after exposure to copper.44 
Genes involved in cell cycle arrest (e.g., p21, reprimo, stathmin, 
Tp53INP1) and apoptotic processes (e.g., IGFBP‑6, PUMA), as 
well as heat‑shock proteins (e.g., Hsp70, Hsp 27) were identified; 
however, their potential role in copper transport has not yet been 
examined. Finally, it is possible that HCT 116+/+ cells express a 
protein spectrum fundamentally different from HCT 116‑/‑ cells in 
quality and quantity even in the ground state before exposed to any 
external stressor like radiation. This implies that the transcription of 
an as of now unknown copper‑binding protein would be activated 
by basal levels of p53.
In summary, the data presented here demonstrate a potential 
mechanism for increased toxicity of 64Cu radiopharmaceuticals for 
targeted radiotherapy of cancer involving the tumor suppressor 
protein p53. Copper‑64 radiopharmaceuticals may show enhanced 
localization of 64Cu in tumor cell nuclei in tumors that express WT 
p53 compared to p53 null or p53 mutant expressing tumor cells. 
This increased localization of 64Cu in the nuclei may cause increased 
DNA damage to cells, and therefore improved tumor cell killing. In 
addition, we have identified a role for p53 in the transport of copper 
into the cell nucleus.
Materials and Methods
Materials. 1,4,7,10‑Tetraazacyclododecane‑1,4,7‑tris(t‑bu
tyl acetate)‑10‑acetic acid mono (N‑hydroxysuccinimide ester) 
[DOTA‑mono‑NHS‑tris(tBu) ester] was purchased from Macrocyclics 
(Dallas, TX). Centricon 100 concentrators were purchased from 
Amicon Inc. (Beverly, MA). All chemicals used were purchased 
from Aldrich Chemical Co. (Milwaukee, WI). All solutions were 
made using distilled deionized water (Milli‑Q; ~18 MW resistivity). 
Monoclonal antibody cetuximab (C225) was kindly provided by 
ImClone Systems (New York, NY). HCT 116 +/+ and HCT 116 
‑/‑ cell lines were kindly provided by Dr. Bert Vogelstein (Johns 
Hopkins University). A Branson Sonifier cell disrupter, and a Sorvall 
RC2‑B centrifuge were used in the receptor binding experiments. 
Size‑exclusion HPLC used in conjugation and purification of radio‑
labeled conjugate was accomplished on a Superose 12 HR 10/300 
column (Amersham Biosciences, Uppsala, Sweden) with a Waters 
(Milford, MA) 2487 dual l absorbance detector and an Ortec Model 
661 (EG&G Instruments, Oak Ridge, TN) radioactive detector. 
The mobile phase was 20 mM HEPES, 150 mM NaCl, pH 7.3 
eluted at a flow rate of 0.5 ml/min. Millenium 32 software (Waters, 
Milford, MA) was used to quantify chromatograms by integration. 
A Beckman 8000 automated well‑typed gamma counter (Fullerton, 
CA) was used to measure internalization and nuclear uptake samples. 
Copper‑64 was produced as previously reported on a biomedical 
cyclotron CS‑15 at Washington University School of Medicine.28
Preparation of 64Cu‑DOTA‑cetuximab. DOTA was conjugated 
to cetuximab in 0.1 M Na2HPO4 (pH 7.5) using an adaptation of 
the method described by Lewis et al.29 Cetuximab (2 mg/ml) was 
washed with 0.1 M Na2HPO4 (pH 7.5) and concentrated using a 
Centricon 100. DOTA‑mono‑NHS‑tris(tBu) ester was dissolved in 
0.1 M Na2HPO4 (pH 7.4) and pH was adjusted to 7.4 by adding 
0.1 M NaOH. An aliquot of this solution was added to the concen‑
trated cetuximab in a molar ratio of DOTA‑mono‑NHS‑tris(tBu) 
ester : cetuximab = 90 : 1, followed by incubation at 4°C overnight 
with end‑over‑end rotation. The conjugate was then transferred to 
a Centricon 100, diluted to 2.0 ml with 0.1 M ammonium citrate 
(pH 5.5), and centrifuged. This procedure was repeated to remove 
small molecule reactants and the conjugate was collected from the 
membrane. Purity and concentration of the resulting conjugate were 
determined by size‑exclusion HPLC, and DOTA‑cetuximab was 
stored at 4°C until needed.
Radiolabeling of DOTA‑cetuximab with 64Cu was carried out 
by adding approximately 100 mg of the conjugate to 0.5–2 mCi 
(19 –74 MBq) 64CuCl2 in 0.1 M ammonium citrate buffer, pH 5.5, 
followed by a 1 h incubation at 40°C. The radiochemical purity of 
the resulting 64Cu‑DOTA‑cetuximab was determined by size‑exclu‑
sion HPLC and radio‑TLC. If necessary, 64Cu‑DOTA‑cetuximab 
was challenged with 5 ml of 10 mM EDTA to complex free 64Cu. 
64Cu‑DOTA‑cetuximab was then isolated with a ZebaTM Desalt 
Spin column (0.5 ml, Pierce, Rockford, IL) to obtain radiochemical 
purities > 95%.
Figure 2. Saturation receptor binding of 64Cu-DOTA-cetuximab to cell 
membranes isolated from HCT 116 cell lines positive (£) and negative (p) 
for p53. Dissociation constants (Kd, 0.95 ± 0.26 nM vs. 1.13 ± 0.22 nM) 
and maximum receptor densities (Bmax, 1,950 ± 180 fmol/mg vs. 2,180 ± 
150 fmol/mg) were similar for HCT 116 +/+ and HCT 116 -/- cell lines, 
respectively (N = 3).
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Binding affinity of 64Cu‑DOTA‑cetuximab. Cell membranes 
from HCT 116+/+ and HCT 116‑/‑ cell lines for binding assays 
were prepared as previously described.30 Assays were performed on a 
96‑well Multiscreen® Durapore filtration plate (Millipore, Billerica, 
MA) using methods previously described with some modifications.31 
Membranes were diluted in binding buffer (50 mM Tris‑HCl, 
pH 7.4, 5 mM MgCl2 · 6 H2O, 0.1% BSA, 0.5 mg/ml aprotinin, 
200 mg/ml bacitracin, 10 mg/ml leupeptin, and 10 mg/ml pepstatin 
A), and 10 mg of membrane protein were used per well. Increasing 
concentrations (0.05 nM–6 nM) of 64Cu‑DOTA‑cetuximab were 
added to membranes to measure total binding, and non‑specific 
binding was determined by conducting the assay in the presence of 
an excess (2 mM) of cetuximab. After incubation at RT for 2 h, the 
medium was removed with a vacuum manifold and the membranes 
were washed twice with 200 ml binding buffer. OptiPhase ‘Super‑Mix’ 
(PerkinElmer, Boston, MA) (25 ml) was added to each well, and 
bound activity was measured with a 1450 Microbeta 
liquid scintillation and luminescence counter (Perkin 
Elmer, Boston, MA). Specific binding was obtained by 
subtraction of non‑specific binding from total binding. 
Maximum binding capacities (Bmax) were estimated 
from non‑linear curve fitting of specific binding 
versus the concentration of 64Cu‑DOTA‑cetuximab 
using GraphPad Prism (San Diego, CA).
Internalization and efflux of [64Cu]copper acetate 
and 64Cu‑DOTA‑cetuximab in HCT 116 cell lines. 
HCT 116 +/+ or HCT 116 ‑/‑ cells were seeded in 
6‑well plates containing growth medium (McCoy’s 5a 
medium with 1.5 mM L‑glutamine adjusted to contain 
2.2 g/l sodium bicarbonate, 90%; fetal bovine serum, 
10%) and were incubated at 37°C, 5% CO2 until 80% 
confluent. On the day of the assay, the medium was 
aspirated and 3 ml fresh growth medium was placed in 
each well. For determination of nonspecific internal‑
ization in the cetuximab experiments, one set of wells 
was incubated with unlabeled cetuximab (375 mg/100 ml) at 37°C, 
5% CO2 for 10 min to block EGF receptors. [
64Cu]copper acetate 
(25 mCi/10 ml) or 64Cu‑DOTA‑cetuximab (3.6 mCi, 0.38 mg/15 
ml) were added to all of the wells and incubated at 37°C, 5% CO2 
for 1, 4 or 24 h. At each time point, radioactive medium was aspi‑
rated, and the plate was washed twice with 2 ml PBS. To collect 
the surface‑bound fraction, each well was treated with 20 mM 
sodium acetate in PBS (pH 3.0) and was incubated at 4°C for 10 
min followed by a second 20 mM sodium acetate in PBS (pH 3.0) 
wash without incubation, which was pooled with the first rinse. 
The cellular fraction was solubilized in 0.1% SDS. All of the frac‑
tions were counted for radioactivity with a gamma counter. The 
percentage internalized was the amount of activity in the final cell 
pellet, corrected for activity in the blocked fractions and background 
activity, and normalized to protein content.
For efflux experiments, cells were seeded in 6‑well plates and 
allowed to adhere overnight. Cells were fed 3 ml fresh growth media 
on the morning of the experiment, 64Cu‑DOTA‑cetuximab was 
added to each well, and cells were incubated at 37°C, 5% CO2 for 
4 h. The radioactive medium was removed and the cells were washed 
twice with ice cold PBS. Fresh growth medium (3 ml) was added to 
each well, and the cells were incubated for 1, 4 or 20 h. At each time 
point, the media was removed and the cells were washed twice with 
ice cold PBS. The cells were solubilized in 0.1% SDS, transferred 
to a microfuge tube, and counted for radioactivity on the gamma 
counter.
Nuclear localization of [64Cu]copper acetate and 64Cu‑DOTA‑ 
cetuximab in HCT 116 cell lines. For isolation of HCT 116 cell 
nuclei, the procedure of Wang et al.14 was used. The experiments 
were performed in T‑175 flasks containing approximately 5 x 107 
cells at the beginning of the time course. 64Cu‑DOTA‑cetuximab 
(4.0 mCi, 0.33 mg/20 ml) was added, and after incubation times 
of 1, 4 and 24 h, the cells were pelleted and resuspended in CSK 
buffer (0.5% Triton X‑100, 300 mM sucrose, 100 mM NaCl, 1 mM 
EGTA, 2 mM MgCl2 and 10 mM PIPES, pH 6.8) and incubated 
on ice for 2 min. Cell lysates were centrifuged at 560 g for 5 min at 
4°C, and the supernatant was discarded. The nuclear pellet was resus‑
pended in 1 ml CSK buffer without Triton X‑100, and centrifuged 
Figure 4. Efflux of 64Cu-DOTA-cetuximab from HCT 116 cell lines positive 
(£) and negative (p) for p53. Efflux is expressed as the percentage of 
retained activity, where the activity at t = 0 (when the radioactive media is 
removed) is 100%.
Figure 3. (A) %ID/mg of 64Cu-DOTA-cetuximab internalized in HCT 116 cell lines positive 
(£) and negative (p) for p53. (B) Percentage of internalized activity localized to the nuclear 
fraction of HCT 116 cells per mg (N = 6 with two independent 64Cu productions).
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at 560 g at 4°C for 5 min. The supernatant was discarded and the 
nuclear pellet was counted with a gamma counter. Aliquots of nuclei 
were assayed qualitatively for purity by fluorescence microscopy after 
staining with a 1:10 dilution of FITC (3 mg/ml) and propidium 
iodide (7 mg/ml). Micrographs were obtained at 100, 200 and 1000 
magnification. The yield of nuclei was determined by counting the 
initial cell number and the collected nuclei using a Coulter Counter. 
The percentage in the cell nucleus was determined by the gamma 
counts in the pure nucleus divided by gamma counts internalized 
into whole cells, and was corrected for the yield of nuclei.
As an additional control in the HCT 116 cell lines, nuclear 
uptake of [64Cu]copper acetate was determined in HCT 116+/+ 
cells after downregulation of p53 by p53 siRNA, and compared 
to untreated HCT 116+/+ and HCT 116‑/‑ cells. Cells were seeded 
in T‑75 flasks so that they were 30–40% confluent after 24 h. 
TransPassTM R1 Transfection Reagent (200 ml; New England 
BioLabs, Boston, MA) was mixed with 5 ml serum‑free medium 
and incubated for 15 min at RT. p53 ShortCut® siRNA Mix 
(20 ml; New England BioLabs) was added, followed by another 15 
min incubation at RT and addition of 43 ml medium with serum. 
This mixture was added to HCT 116+/+ cells (12 ml/flask) and the 
cells were grown for 48 h under standard conditions. A change to 
fresh medium was followed by additional 24 h of incubation, and 
nuclear localization experiments were then conducted as described 
above.
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